Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis.
作者信息
Zhu Jieyun, Pang Jielong, Ji Pan, Zhong Zhimei, Li Hongyuan, Li Bocheng, Zhang Jianfeng
机构信息
Department of Emergency Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
出版信息
J Med Virol. 2021 Jan;93(1):35-37. doi: 10.1002/jmv.26085. Epub 2020 Oct 30.
Abstract
摘要
相似文献
1
Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis.白细胞介素-6升高与新型冠状病毒肺炎严重程度相关：一项荟萃分析。
J Med Virol. 2021 Jan;93(1):35-37. doi: 10.1002/jmv.26085. Epub 2020 Oct 30.
2
Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis.循环白细胞介素-6 和白细胞介素-10 水平，而不是肿瘤坏死因子-α，作为 COVID-19 严重程度和死亡率的潜在生物标志物：系统评价与荟萃分析。
J Clin Immunol. 2021 Jan;41(1):11-22. doi: 10.1007/s10875-020-00899-z. Epub 2020 Oct 31.
3
Elements of Th1/Th2 response and disease severity in COVID-19 patients: A short report.新型冠状病毒肺炎患者 Th1/Th2 反应及疾病严重程度的相关因素：一项简短报告。
J Med Virol. 2022 Jan;94(1):404-406. doi: 10.1002/jmv.27313. Epub 2021 Sep 4.
4
Interleukin-6 and severity of COVID-19 patients in Hefei, China.中国合肥的白细胞介素 6 与 COVID-19 患者严重程度的关系。
Med Mal Infect. 2020 Oct;50(7):629-631. doi: 10.1016/j.medmal.2020.06.005. Epub 2020 Jun 25.
5
Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan.武汉 COVID-19 患者炎症反应和结局的性别影响。
J Med Virol. 2020 Nov;92(11):2684-2692. doi: 10.1002/jmv.26137. Epub 2020 Jun 19.
6
Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression.入院时免疫反应标志物与 COVID-19 疾病严重程度和死亡率的关系：荟萃分析和荟萃回归。
J Med Virol. 2021 Feb;93(2):1078-1098. doi: 10.1002/jmv.26411. Epub 2020 Sep 28.
7
sTREM-1 Predicts Disease Severity and Mortality in COVID-19 Patients: Involvement of Peripheral Blood Leukocytes and MMP-8 Activity.sTREM-1 预测 COVID-19 患者的疾病严重程度和死亡率：外周血白细胞和 MMP-8 活性的参与。
Viruses. 2021 Dec 15;13(12):2521. doi: 10.3390/v13122521.
8
Interleukin-6 as a potential biomarker of COVID-19 progression.白细胞介素-6作为新冠病毒疾病进展的潜在生物标志物。
Med Mal Infect. 2020 Jun;50(4):382-383. doi: 10.1016/j.medmal.2020.04.002. Epub 2020 Apr 4.
9
Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19.失调的固有和适应性免疫反应可区分 COVID-19 的疾病严重程度。
J Infect Dis. 2021 Apr 23;223(8):1322-1333. doi: 10.1093/infdis/jiab065.
10
Therapeutic plasma exchange therapy support for critical COVID-19: A case report.治疗性血浆置换疗法对重症新型冠状病毒肺炎的支持：一例病例报告。
Ther Apher Dial. 2021 Aug;25(4):533-535. doi: 10.1111/1744-9987.13586. Epub 2020 Nov 3.
引用本文的文献
1
Inflammatory, fibrotic and endothelial biomarker profiles in COVID-19 patients during and following hospitalization.新冠病毒肺炎患者住院期间及出院后的炎症、纤维化和内皮生物标志物谱
Sci Rep. 2025 Jul 10;15(1):24850. doi: 10.1038/s41598-025-09245-y.
2
Chronic Hepatitis B and COVID-19 Clinical Outcomes in the United States: A Multisite Retrospective Cohort Study.美国慢性乙型肝炎与新冠病毒病的临床结局：一项多中心回顾性队列研究
Open Forum Infect Dis. 2025 Jan 10;12(2):ofaf013. doi: 10.1093/ofid/ofaf013. eCollection 2025 Feb.
3
Pathophysiological, Neuropsychological, and Psychosocial Influences on Neurological and Neuropsychiatric Symptoms of Post-Acute COVID-19 Syndrome: Impacts on Recovery and Symptom Persistence.急性 COVID-19 综合征后神经和神经精神症状的病理生理、神经心理及社会心理影响：对恢复及症状持续的影响
Biomedicines. 2024 Dec 13;12(12):2831. doi: 10.3390/biomedicines12122831.
4
The Impact of Infliximab on Hyperinflammation State in Hospitalized COVID-19 Patients: A Retrospective Study.英夫利昔单抗对住院 COVID-19 患者过度炎症状态的影响：一项回顾性研究。
Medicina (Kaunas). 2024 Oct 11;60(10):1670. doi: 10.3390/medicina60101670.
5
Intravenous Tocilizumab versus Standard of Care in the Treatment of Severe and Critical COVID-19-related Pneumonia: A Single-center, Double-blind, Placebo-controlled, Phase 3 Trial.托珠单抗静脉注射对比标准治疗方案用于治疗重度及危重型新型冠状病毒肺炎相关肺炎：一项单中心、双盲、安慰剂对照的3期试验
Acta Med Philipp. 2024 Apr 15;58(6):7-13. doi: 10.47895/amp.vi0.6175. eCollection 2024.
6
Appropriate Use of Tocilizumab in COVID-19: Early Use is Beneficial.妥珠单抗在新冠病毒疾病中的合理使用：早期使用有益。
Infect Dis Clin Microbiol. 2022 Jun 13;4(2):116-121. doi: 10.36519/idcm.2022.116. eCollection 2022 Jun.
7
The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges.2019冠状病毒病中炎症与血栓形成的相互作用：机制、治疗策略及挑战
Thromb Update. 2022 Aug;8:100117. doi: 10.1016/j.tru.2022.100117. Epub 2022 Jul 9.
8
Correlation between interleukin-6 expression in post-mortem core liver biopsy and degree of liver injury in patients with fatal COVID-19.新冠死亡患者尸检肝脏活检核心组织中白细胞介素-6表达与肝损伤程度的相关性
Narra J. 2023 Dec;3(3):e463. doi: 10.52225/narra.v3i3.463. Epub 2023 Dec 6.
9
Successful Recovery of COVID-19 Associated With Cardiomyopathy in Advanced Breast Cancer Patient With Pulmonary Lymphangitis Carcinomatosis.晚期乳腺癌合并肺淋巴管癌病患者新冠病毒病伴心肌病成功康复
Clin Med Insights Case Rep. 2023 Dec 6;16:11795476231210142. doi: 10.1177/11795476231210142. eCollection 2023.
10
Comparative effectiveness of tocilizumab vs standard care in patients with severe COVID-19-related pneumonia: a retrospective cohort study utilizing registry data as a synthetic control.托珠单抗对比标准治疗用于重症 COVID-19 相关肺炎患者的疗效比较：一项利用登记数据作为合成对照的回顾性队列研究。
BMC Infect Dis. 2023 Dec 4;23(1):849. doi: 10.1186/s12879-023-08840-6.
本文引用的文献
1
Elevated interleukin-6 and severe COVID-19: A meta-analysis.白细胞介素-6升高与重症新型冠状病毒肺炎：一项荟萃分析。
J Med Virol. 2020 Nov;92(11):2283-2285. doi: 10.1002/jmv.25948. Epub 2020 Jun 2.
2
Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019.在重症 2019 冠状病毒病患者中，可检测到的血清严重急性呼吸综合征冠状病毒 2 病毒载量（RNAemia）与显著升高的白细胞介素 6 水平密切相关。
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942. doi: 10.1093/cid/ciaa449.
3
Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients.冠状病毒（COVID-19）感染患者的淋巴细胞亚群、细胞因子与肺部炎症指数之间的关系。
Br J Haematol. 2020 May;189(3):428-437. doi: 10.1111/bjh.16659. Epub 2020 Apr 20.
4
Interleukin-6 as a potential biomarker of COVID-19 progression.白细胞介素-6作为新冠病毒疾病进展的潜在生物标志物。
Med Mal Infect. 2020 Jun;50(4):382-383. doi: 10.1016/j.medmal.2020.04.002. Epub 2020 Apr 4.
5
[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].[29例2019新型冠状病毒肺炎患者临床特征分析]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):203-208. doi: 10.3760/cma.j.issn.1001-0939.2020.03.013.
6
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.中国武汉 2019 年冠状病毒病（COVID-19）患者免疫反应失调。
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
7
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.纽卡斯尔-渥太华量表在荟萃分析中评估非随机研究质量的批判性评价。
Eur J Epidemiol. 2010 Sep;25(9):603-5. doi: 10.1007/s10654-010-9491-z. Epub 2010 Jul 22.
8
Estimating the mean and variance from the median, range, and the size of a sample.根据中位数、极差和样本量估计均值和方差。
BMC Med Res Methodol. 2005 Apr 20;5:13. doi: 10.1186/1471-2288-5-13.
9
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.流行病学观察性研究的Meta分析：报告建议。流行病学观察性研究的Meta分析（MOOSE）小组。
JAMA. 2000 Apr 19;283(15):2008-12. doi: 10.1001/jama.283.15.2008.
Zotero 插件